We are a clinical research organisation with a singular purpose: to accelerate the translation of clinical evidence into improved patient outcomes.
KCLG Medical was founded on the recognition that high-quality clinical research often fails to reach the patients who need it most. The journey from a statistically significant trial result to a changed prescribing decision — let alone a changed life — is longer, harder, and more uncertain than it should be.
We were established to shorten that journey. Working at the intersection of rigorous methodology, clinical expertise, and patient partnership, KCLG Medical designs and delivers trials that are not only scientifically sound but practically implementable within the NHS and broader healthcare systems.
From our founding focus on haematological malignancies and precision oncology to our expanding portfolio across metabolic medicine, our work has always been driven by the same question: What will it take for this finding to actually help a patient?
"Every day that a proven therapy sits in a journal instead of a clinic, a patient who could have benefited doesn't. Our work exists to close that gap — rigorously, ethically, and urgently."— KCLG Medical Research Team
We design evidence-based trials with pre-specified endpoints, independent oversight, and full publication commitment — regardless of result.
We envision clinical practice continuously informed by robust, reproducible research — with no proven therapy left sitting unused in a journal.
Every study we conduct, every paper we publish, and every clinician we engage is part of our effort to shorten the distance from discovery to bedside.
We pre-register every trial, pre-specify our analysis plans, and publish all results — positive, negative, or inconclusive. Sound methodology is non-negotiable.
Every participant is a person first. Informed consent, honest communication, and participant welfare sit at the centre of every protocol we design.
We actively work to ensure our trials reflect the diversity of patients who will ultimately use the treatments we study — including underrepresented groups.
Pre-registration, open access publishing where possible, and full disclosure of funding sources and potential conflicts are standard practice for us — not aspirations.
We treat every trial — including those that do not confirm our hypothesis — as an opportunity to refine our understanding and improve future study design.
We embrace adaptive trial designs, biomarker stratification, and patient co-design — not for novelty, but because they produce better evidence faster.
